Literature DB >> 19684633

Total body MRI-governed involved compartment irradiation combined with high-dose chemotherapy and stem cell rescue improves long-term survival in Ewing tumor patients with multiple primary bone metastases.

S Burdach1, U Thiel, M Schöniger, R Haase, A Wawer, M Nathrath, H Kabisch, C Urban, H J Laws, U Dirksen, M Steinborn, J Dunst, H Jürgens.   

Abstract

We examined the role of total body magnetic resonance imaging (TB-MRI)-governed involved compartment irradiation (ICI) and high-dose chemotherapy (HDC), followed by stem cell rescue (SCR) in patients with high-risk Ewing tumors (ETs) with multiple primary bone metastases (high-risk ET-MBM). Eleven patients with high-risk ET-MBM receiving initial assessment of involved bones by TB-MRI were registered from 1995 to 2000 (group A). In all, 6 patients out of 11 had additional lung disease at initial diagnosis; all had multifocal bone disease with more than three bones involved. After systemic induction with etoposide, vincristine, adriamycin (doxorubicin), ifosfamide, and actinomycin D (EVAIA) or VAIA chemotherapy, ICI of all sites positive by TB-MRI was administered, followed by HDC and SCR. A second group matched for observation period and consisting of 26 patients with more than three involved bones at diagnosis was treated with the European Intergroup Cooperative Ewing Sarcoma Study-92 (EICESS-92) protocol (group B). These patients did not receive TB-MRI and consequently did not receive TB-MRI-governed ICI, or HDC and SCR. Survival in group A vs group B was 45 vs 8% at 5 years and 27 vs 8% at 10 years after diagnosis (log rank and Breslow: P<0.005). We conclude that TB-MRI-governed ICI followed by HDC and SCR in ET-MBM is feasible and warrants further evaluation in prospective studies.

Entities:  

Mesh:

Year:  2009        PMID: 19684633     DOI: 10.1038/bmt.2009.184

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  11 in total

1.  Transgenic antigen-specific, HLA-A*02:01-allo-restricted cytotoxic T cells recognize tumor-associated target antigen STEAP1 with high specificity.

Authors:  David Schirmer; Thomas G P Grünewald; Richard Klar; Oxana Schmidt; Dirk Wohlleber; Rebeca Alba Rubío; Wolfgang Uckert; Uwe Thiel; Felix Bohne; Dirk H Busch; Angela M Krackhardt; Stefan Burdach; Günther H S Richter
Journal:  Oncoimmunology       Date:  2016-04-25       Impact factor: 8.110

2.  Token economy to improve adherence to activities of daily living.

Authors:  Victoria Hickey; Laura Flesch; Adam Lane; Ahna L H Pai; John Huber; Priscila Badia; Stella M Davies; Christopher E Dandoy
Journal:  Pediatr Blood Cancer       Date:  2018-07-26       Impact factor: 3.167

Review 3.  Optimal management of Ewing sarcoma family of tumors: recent developments in systemic therapy.

Authors:  Cormac Owens; Lesleigh S Abbott; Abha A Gupta
Journal:  Paediatr Drugs       Date:  2013-12       Impact factor: 3.022

4.  Specific recognition and inhibition of Ewing tumour growth by antigen-specific allo-restricted cytotoxic T cells.

Authors:  U Thiel; S Pirson; C Müller-Spahn; H Conrad; D H Busch; H Bernhard; S Burdach; G H S Richter
Journal:  Br J Cancer       Date:  2011-03-15       Impact factor: 7.640

5.  Mesenchymal stromal cells for treatment of steroid-refractory GvHD: a review of the literature and two pediatric cases.

Authors:  Caroline M Wernicke; Thomas Gp Grunewald; Juenger Hendrik; Selim Kuci; Zyrafete Kuci; Ulrike Koehl; Ingo Mueller; Michaela Doering; Christina Peters; Anita Lawitschka; Hans-Jochem Kolb; Peter Bader; Stefan Burdach; Irene von Luettichau
Journal:  Int Arch Med       Date:  2011-08-15

6.  Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma.

Authors:  Tim Hensel; Chiara Giorgi; Oxana Schmidt; Julia Calzada-Wack; Frauke Neff; Thorsten Buch; Felix K Niggli; Beat W Schäfer; Stefan Burdach; Günther H S Richter
Journal:  Oncotarget       Date:  2016-01-12

7.  The endochondral bone protein CHM1 sustains an undifferentiated, invasive phenotype, promoting lung metastasis in Ewing sarcoma.

Authors:  Kristina von Heyking; Julia Calzada-Wack; Stefanie Göllner; Frauke Neff; Oxana Schmidt; Tim Hensel; David Schirmer; Annette Fasan; Irene Esposito; Carsten Müller-Tidow; Poul H Sorensen; Stefan Burdach; Günther H S Richter
Journal:  Mol Oncol       Date:  2017-08-21       Impact factor: 6.603

8.  Bone marrow involvement identifies a subgroup of advanced Ewing sarcoma patients with fatal outcome irrespective of therapy in contrast to curable patients with multiple bone metastases but unaffected marrow.

Authors:  Uwe Thiel; Angela Wawer; Irene von Luettichau; Hans-Ulrich Bender; Franziska Blaeschke; Thomas G P Grunewald; Marc Steinborn; Barbara Röper; Halvard Bonig; Thomas Klingebiel; Peter Bader; Ewa Koscielniak; Michael Paulussen; Uta Dirksen; Heribert Juergens; Hans-Jochem Kolb; Stefan E G Burdach
Journal:  Oncotarget       Date:  2016-10-25

Review 9.  Non-odontogenic tumors of the facial bones in children and adolescents: role of multiparametric imaging.

Authors:  Minerva Becker; Salvatore Stefanelli; Anne-Laure Rougemont; Pierre Alexandre Poletti; Laura Merlini
Journal:  Neuroradiology       Date:  2017-03-13       Impact factor: 2.804

10.  Whole-body magnetic resonance imaging in pediatric oncology - recommendations by the Oncology Task Force of the ESPR.

Authors:  Jürgen F Schäfer; Claudio Granata; Thekla von Kalle; Martin Kyncl; Annemieke S Littooij; Pier Luigi Di Paolo; Irmina Sefic Pasic; Rutger A J Nievelstein
Journal:  Pediatr Radiol       Date:  2020-05-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.